ArticleBMC endocrine disorders2025
The association of plasma testosterone level and progression of diabetic nephropathy in male.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD), significantly impacting the global burden of diabetes mellitus (DM). Testosterone has been implicated in the pathophysiology of DN, yet its specific role remains unclear.
methodsThis retrospective cohort study analyzed 347 male patients with type 2 diabetes mellitus (T2DM), including 165 with DN and 182 without DN, to explore the relationship between plasma testosterone levels and DN progression. Clinical and biochemical data were collected, and univariate, multivariate regression, and logistic regression analyses were performed. A nomogram predictive model was developed incorporating DN risk factors.
resultsNo significant difference in plasma testosterone levels was observed between DN and DM patients. However, testosterone levels varied significantly across DN stages, peaking in stage G5. Multivariate analysis identified testosterone (OR = 3.13, 95% CI [1.25-8.87]) as an independent risk predictor for poor DN prognosis. The predictive model combining Cyc, testosterone, Age, SBP, DBP, UACR, and demonstrated excellent prediction for the adverse outcomes in DN. (AUC = 0.923, 95% CI: 0.891-1).
conclusionTestosterone plays critical roles in DN progression and prognosis. The developed nomogram offers a practical tool for risk stratification and management of male DN patients. Further research is needed to validate these findings and elucidate the mechanistic pathways linking testosterone to DN progression. CLINICAL TRIAL NUMBER: No applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.